Fierce Healthcare

JULY 9, 2023

The federal government will pay eligible hospitals in the 340B program $9 billion to offset payment cuts the Supreme Court ruled unlawful last year. | The federal government will pay eligible hospitals in the 340B program $9 billion to offset payment cuts the Supreme Court ruled unlawful last year.

Hospitals 115

Hospitals 115

pharmaphorum

JULY 9, 2023

Novartis will appeal Entresto patent setback Phil.

98

98

Med Ed 101

JULY 9, 2023

Patients use numerous supplements that contain vitamins. I outline my top 5 vitamin drug interactions in this post and how they may impact patient care. Vitamin K and Warfarin The first vitamin drug interaction you could probably guess. Vitamin K intake affects warfarin and ultimately a patient’s INR. Consistent intake is recommended when taking warfarin. […] The post Top 5 Vitamin Drug Interactions appeared first on Med Ed 101.

Patient Care 52

Patient Care 52

Pharmaceutical Technology

JULY 9, 2023

In this issue: Artificial intelligence tools for patients, EU funding for British biotech, analytics for continuous manufacturing, Apple’s play for the metaverse.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

BioPharm

JULY 9, 2023

There has been a Growing concern among regulators driving a need for awareness for manufacturers to understand the risk associated with nitrosamines in pharmaceutical and biopharmaceutical products. In this session of Changing the Conversation with SGS Live, we tackled a variety of aspects of this important issue from the risk associated with nitrosamine contamination to discovery and mitigation of nitrosamine impurities.

40

40

BioPharm

JULY 9, 2023

Discovery why evaluating a CMO’s internal processes, facilities, capacity, capabilities, and communication is key to successful ophthalmic scale up and manufacturing.

Communication 40

Communication 40